Literature DB >> 2253318

Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats.

M Qi1, S B Jones.   

Abstract

The effect of the platelet activating factor (PAF) antagonist WEB 2086 on blood pressure; heart rate; and plasma glucose, lactate, and catecholamine concentrations were examined following either PAF or endotoxin administration in conscious rats. PAF infusion (50 ng/kg/min for 60 min) resulted in a sustained hypotension, with tachycardia and elevated plasma norepinephrine (NE; 1.8-fold increase), epinephrine (E; 6.7-fold increase), and dopamine (DA; 1.0-fold increase) at 30 min after beginning infusion. Plasma NE, E, and DA became 4.1 (NE)-, 17.4 (E)-, and 3.3 (DA)-fold higher than control at 60 min after beginning infusion. Both the hemodynamic and plasma catecholamine alterations induced with PAF were completely blocked with WEB 2086 pretreatment. Bacterial endotoxin treatment (5 mg/kg, i.v. bolus) produced well-characterized responses of hypotension, tachycardia, hyperglycemia, hyperlactacidemia, and an elevation in plasma catecholamines. Whereas complete blockade of the hypotensive and tachycardic effect of endotoxin was achieved with WEB 2086 at 30 min following endotoxin, the increases in plasma catecholamines and lactate elicited by endotoxin were attenuated but remained significantly higher than control levels. Hyperglycemia following endotoxin was not altered by WEB 2086 treatment. In endotoxic rats pretreated with WEB 2086 there was significant hypotension, tachycardia, and hyperlactacidemia and an elevation in plasma catecholamines at both 60 and 120 min, but all were less severe compared to non-WEB 2086-treated endotoxic animals. The results demonstrate that WEB 2086 completely blocked early endotoxin-induced hypotension and tachycardia but not catecholamine elevation following endotoxin. This work suggests that sympathetic activation following endotoxin may be mediated by factors other than hypotension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253318

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  5 in total

Review 1.  Clinical experience with platelet-activating factor antagonists. Past, present, and near future.

Authors:  P Guinot
Journal:  Clin Rev Allergy       Date:  1994

2.  Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock.

Authors:  S J De Kimpe; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

3.  Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock.

Authors:  M Giral; D Balsa; R Ferrando; M Merlos; J Garcia-Rafanell; J Forn
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

4.  Endotoxin-induced enhancement of glucose influx into murine peritoneal macrophages via GLUT1.

Authors:  M Fukuzumi; H Shinomiya; Y Shimizu; K Ohishi; S Utsumi
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

5.  A circulating shock protein depolarizes cells in hemorrhage and sepsis.

Authors:  B J Eastridge; D N Darlington; J A Evans; D S Gann
Journal:  Ann Surg       Date:  1994-03       Impact factor: 12.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.